NIHR - Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Molecular Medicine, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK.
Arthritis Res Ther. 2010;12(2):R57. doi: 10.1186/ar2969. Epub 2010 Mar 30.
This study investigated five confirmed rheumatoid arthritis (RA) susceptibility genes/loci (HLA-DRB1, PTPN22, STAT4, OLIG3/TNFAIP3 and TRAF1/C5) for association with susceptibility and severity in an inception cohort.
The magnitude of association for each genotype was assessed in 1,046 RA subjects from the Yorkshire Early RA cohort and in 5,968 healthy UK controls. Additional exploratory subanalyses were undertaken in subgroups defined by autoantibody status (rheumatoid factor and anti-cyclic citrullinated peptide) or disease severity (baseline articular erosions, Health Assessment Questionnaire (HAQ) score and swollen joint count (SJC)).
In the total RA inception cohort, the HLA-DRB1 shared epitope (per-allele odds ratio (OR) = 2.1, trend P < 0.0001), PTPN22 (per-allele OR = 1.5, trend P < 0.0001), OLIG3/TNFAIP3 locus (per-allele OR = 1.2, trend P = 0.009) and TRAF1/C5 locus (per-allele OR = 1.1, trend P = 0.04) were associated with RA. The magnitude of association for these loci was increased in those patients who were autoantibody-positive. PTPN22 was associated with autoantibody-negative RA (per-allele OR = 1.3, trend P = 0.04). There was no evidence of association between these five genetic loci and baseline erosions or SJC in the total RA cohort, after adjustment for symptom duration. TRAF1/C5 was significantly associated with baseline HAQ, however, following adjustment for symptom duration (P trend = 0.03).
These findings support the mounting evidence that different genetic loci are associated with autoantibody-positive and autoantibody-negative RA, possibly suggesting that many of the genes identified to date are associated with autoantibody production. Additional studies with a specific focus on autoantibody-negative RA will be needed to identify the genes predisposing to this RA subgroup. The TRAF1/C5 locus in particular warrants further investigation in RA as a potential disease severity locus.
本研究旨在探讨五个已确定的类风湿关节炎(RA)易感基因/位点(HLA-DRB1、PTPN22、STAT4、OLIG3/TNFAIP3 和 TRAF1/C5)与发病和严重程度的相关性,研究对象为一个发病队列。
在约克郡早期 RA 队列中的 1046 名 RA 患者和 5968 名健康的英国对照者中,评估了每种基因型的关联程度。根据自身抗体状态(类风湿因子和抗环瓜氨酸肽)或疾病严重程度(基线关节侵蚀、健康评估问卷(HAQ)评分和肿胀关节计数(SJC))对亚组进行了额外的探索性分析。
在 RA 发病队列中,HLA-DRB1 共享表位(每等位基因优势比(OR)=2.1,趋势 P<0.0001)、PTPN22(每等位基因 OR=1.5,趋势 P<0.0001)、OLIG3/TNFAIP3 基因座(每等位基因 OR=1.2,趋势 P=0.009)和 TRAF1/C5 基因座(每等位基因 OR=1.1,趋势 P=0.04)与 RA 相关。这些基因座与自身抗体阳性患者的相关性更强。PTPN22 与自身抗体阴性 RA 相关(每等位基因 OR=1.3,趋势 P=0.04)。在调整症状持续时间后,这些基因座与 RA 患者的基线侵蚀或 SJC 之间没有关联。然而,TRAF1/C5 与基线 HAQ 显著相关,但在调整症状持续时间后(P 趋势=0.03)。
这些发现支持越来越多的证据表明,不同的基因座与自身抗体阳性和自身抗体阴性 RA 相关,这可能表明迄今为止发现的许多基因与自身抗体的产生有关。需要对自身抗体阴性 RA 进行专门研究,以确定易患该 RA 亚组的基因。TRAF1/C5 基因座特别值得在 RA 中进一步研究,作为一个潜在的疾病严重程度基因座。